Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bvt.115959. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 13/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 12/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bvt.115959 SCHEMBL12012980 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL13863558 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL990077 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL13224547 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL13224527 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL24838605 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| Bvt.115959 SCHEMBL4408531 | 0.98 | ADORA2A (0.96) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8622034 | 0.90 | ADORA2A (0.82) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2777661 | 0.90 | ADORA2A (0.82) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8622040 | 0.90 | ADORA2A (0.82) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| EP-4008334-B1 | MANNOSE-BASED MRNA TARGETED DELIVERY SYSTEM AND USE THEREOF | SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD (CN) | 2024-12-04 | — | — | EP | claimed |
| CN-113423430-B | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240358773-A1 | Parabacteroides Goldsteinii to Treat or Prevent Inflammatory and AutoImmune Diseases | JOSLIN DIABETES CENTER (US) | 2024-10-31 | — | — | US | claimed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118451106-A | Combination therapy of Claudin 18.2 antagonists and PD-1/PD-L1 axis inhibitors | 苏州创胜医药集团有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118252942-A | Cell membrane bionic preparation with spongiform factor effect and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2024-06-28 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| CN-1809365-A | Use of adenosine receptor agonists in therapy | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2006-07-26 | — | — | CN | claimed |
| CN-1750835-A | Compounds for the treatment of pain | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2006-03-22 | — | — | CN | claimed |
| EP-1603576-A1 | USE OF ADENOSINE RECEPTOR AGONISTS IN THERAPY | Cambridge Biotechnology Ltd (GB) | 2005-12-14 | — | — | EP | claimed |
| EP-1603577-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | Cambridge Biotechnology Ltd (GB) | 2005-12-14 | — | — | EP | claimed |
| WO-2005056571-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2005-06-23 | — | — | WO | claimed |
| WO-2004078183-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2004-09-16 | — | — | WO | claimed |
| WO-2004078184-A1 | USE OF ADENOSINE RECEPTOR AGONISTS IN THERAPY | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2004-09-16 | — | — | WO | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA2A 70/4885ADORA2B 200/4885ADORA3 102/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA2A 70/4885ADORA2B 200/4885ADORA3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.